ABSTRACT
Background Parkinson’s disease psychosis (PDP) has a major impact on quality of life and care partner burden; however, little is known about the lived experiences of care partners in managing PDP.
Objective To understand how care partners of individuals with PDP experience their role and articulate their needs related to psychosis.
Methods This was a qualitative study of semi-structured telephone interviews. Recruitment was conducted online via the clinical study matching tool, Fox Trial Finder; study activities took place remotely via telephone interviews. Transcripts of the phone interviews were analyzed by grounded theory methods, and a codebook of key themes that emerged from the analysis was developed.
Results Nine care partners (all female) were interviewed. Discussion topics in the codebook included (1) care partner burden and guilt; (2) communication with medical professionals; (3) coping strategies; (4) emotional reactions of the care partner to psychosis; (5) sources of knowledge about PD psychosis; (6) attitudes towards medications for PDP; (7) strategies to care for loved ones with psychosis; (8) psychosis triggers.
Conclusions This qualitative analysis uncovers important aspects of the care partner experience, including challenges in navigating the medical system and communicating with professionals. Providers treating patients with PDP should be aware of these constraints and provide added support for strained care partners.
Competing Interest Statement
Author SM receives research support from the Michael J Fox Foundation (MJFF), from the Parkinson Foundation (PF), and from Cerevel Therapeutics, was a paid consultant to MJFF, is a study site investigator for a study sponsored by Neuraly Rho, is a study site sub-investigator for a study sponsored by Biogen, and received consulting fees from Deep Brain Innovations, LLC. Author CM receives research support from MJFF, from the Canadian Institutes of Health Research, from PF, and from the International Parkinsons and Movement Disorder Society, and is a site investigator for a research study supported by Theravance Biopharma. Author LMC receives research support from MJFF, receives research support from the UPMC Competitive Medical Research Fund, is study site investigator for a study sponsored by Biogen, receives research support from the National Institutes of Health, receives royalties from Elsevier (for authorship), and receives royalties from Wolters Kluwel (for authorship). This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
Funding Statement
The Michael J Fox Foundation (MJFF), which sponsored this study, is funded by ACADIA Pharmaceuticals, Adamas Pharmaceuticals, Intec Pharma, Lundbeck Inc., and Sunovion Pharmaceutical.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the New England IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data cannot be shared publicly because they consist of potentially identifiable audio recordings. This requirement is set by the New England IRB who approved the study. Data are available from the Michael J. Fox Foundation (contact: Bernadette Siddiqui, bsiddiqui{at}michaeljfox.org) for researchers who meet the criteria for access to confidential data
